Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 220

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 220
---
116 Figure 1 Figure 1:In vitro pigment inhibition by compound ALS -4: Inhibition of staphyloxathin (the golden pigment in S. Aureus) in the presence of increasing concentrations of ALS -4 Efficacy of ALS-4 in a MRSA Wound Infection Mouse Model A study conducted by a third -partycontract research organization, assessed ALS -4’s effect in the healing of open wounds infected with MRSA in a mouse model. Compared with topical dosing of 2% Mupirocin and oral dosing of Linezolid at 100mg/kg twice a day, oral dosing of ALS -4at 30mg/kg twice a day showed statistically 117 significant improvement in wound healing. Specifically, at the end of the study on Day7, ALS -4exhibited 63.8% of wound closure compared with 48.4% for oral Linezolid and 43.2% for topical Mupirocin 2%. The results are further illustrated in the graph below. Figure 2 ____________ *Unpaired student’s t -test, p<0.05 Figure 2:Result of study on ALS -4’s effect in the healing of open wounds infected with MRSA in a mouse model Efficacy of ALS-4 in a Bacteraemia Mouse Model In a further round of in vivostudies, conducted by a third -partycontract research organization, in a non -lethalMRSA bacteraemia mouse model, the mice were orally administered with different doses of ALS -4from 0.3 to 30mg/kg twice a day for 7 days, compared to those who received vancomycin only group (3mg/kg of vancomycin administered intravenously) and a no treatment control group. At the conclusion of the study on Day7, ALS -4brought a statistically significant reduction in bacterial counts in major organs such as the kidneys, lungs, liver and spleen compared with the no drug control and vancomycin only groups (unpaired student’s t -test, p<0.05). This is in addition to the previous in vivoresults announced in February 2020, 118 whereby ALS -4demonstrated on a statistically significant basis better survival rates (56% vs 0% control group) in the lethal MRSA bacteraemia rat model (Figure 3a) and higher reduction of bacterial load (by 99.5% against the control